KR20110036609A - 피페리디닐 ｇｐｃｒ 작용제 - Google Patents

피페리디닐 ｇｐｃｒ 작용제 Download PDF

Info

Publication number
KR20110036609A
KR20110036609A KR1020117002904A KR20117002904A KR20110036609A KR 20110036609 A KR20110036609 A KR 20110036609A KR 1020117002904 A KR1020117002904 A KR 1020117002904A KR 20117002904 A KR20117002904 A KR 20117002904A KR 20110036609 A KR20110036609 A KR 20110036609A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
compound according
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117002904A
Other languages
English (en)
Korean (ko)
Inventor
리사 사라 베르트람
매튜 콜린 토르 파이프
레바티 페르페투아 지바라트남
존 케일리
토마스 마르틴 크룰레
크리스텔 마리 라사미슨
콜린 피터 샘브룩-스미스
시몬 앤드류 스와인
Original Assignee
프로시디온 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0812646A external-priority patent/GB0812646D0/en
Priority claimed from GB0812622A external-priority patent/GB0812622D0/en
Priority claimed from GB0902391A external-priority patent/GB0902391D0/en
Application filed by 프로시디온 리미티드 filed Critical 프로시디온 리미티드
Publication of KR20110036609A publication Critical patent/KR20110036609A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117002904A 2008-07-10 2009-07-10 피페리디닐 ｇｐｃｒ 작용제 Withdrawn KR20110036609A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0812646A GB0812646D0 (en) 2008-07-10 2008-07-10 Compounds
GB0812622A GB0812622D0 (en) 2008-07-10 2008-07-10 Compounds
GB0812646.8 2008-07-10
GB0812622.9 2008-07-10
GB0902391.2 2009-02-13
GB0902391A GB0902391D0 (en) 2009-02-13 2009-02-13 Compounds

Publications (1)

Publication Number Publication Date
KR20110036609A true KR20110036609A (ko) 2011-04-07

Family

ID=41070447

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117002904A Withdrawn KR20110036609A (ko) 2008-07-10 2009-07-10 피페리디닐 ｇｐｃｒ 작용제

Country Status (15)

Country Link
US (1) US20110269734A1 (OSRAM)
EP (1) EP2321297A1 (OSRAM)
JP (1) JP2011527331A (OSRAM)
KR (1) KR20110036609A (OSRAM)
CN (1) CN102083813A (OSRAM)
AU (1) AU2009269772A1 (OSRAM)
CA (1) CA2728042A1 (OSRAM)
CL (1) CL2011000051A1 (OSRAM)
EA (1) EA201170151A1 (OSRAM)
IL (1) IL209978A0 (OSRAM)
MA (1) MA32467B1 (OSRAM)
MX (1) MX2011000060A (OSRAM)
PE (1) PE20110329A1 (OSRAM)
WO (1) WO2010004343A1 (OSRAM)
ZA (1) ZA201008955B (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110053949A1 (en) * 2008-04-17 2011-03-03 Pfizer Inc. 4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
GB0904285D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904284D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
BRPI1010795B1 (pt) 2009-05-13 2018-12-11 Gilead Pharmasset Llc compostos antivirais, seu uso e composição farmacêutica compreendendo os mesmos
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
AU2010264720A1 (en) 2009-06-24 2011-12-08 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
WO2010149685A1 (en) 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh New compounds, pharmaceutical composition and methods relating thereto
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
GB201006167D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB201006166D0 (en) 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012066077A1 (en) 2010-11-18 2012-05-24 Prosidion Limited 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
GB201114389D0 (en) 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
WO2012138845A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012173917A1 (en) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AP2014007575A0 (en) 2011-09-16 2012-04-30 Gilead Pharmasset Llc Methods for treating HCV
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
WO2013062838A1 (en) 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2013074388A1 (en) 2011-11-15 2013-05-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as gpr119 agonists
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
WO2018068295A1 (en) * 2016-10-14 2018-04-19 Merck Sharp & Dohme Corp. ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR β AGONISTS, COMPOSITIONS, AND THEIR USE
KR20220150270A (ko) * 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
JP7745559B2 (ja) 2020-02-28 2025-09-29 キャリーオペ，インク． Ｇｐｒ４０アゴニスト
CN117321059A (zh) 2021-05-21 2023-12-29 吉利德科学公司 用于治疗寨卡病毒感染的四环化合物
CN117460734A (zh) 2021-05-21 2024-01-26 吉利德科学公司 作为寨卡病毒抑制剂的五环衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1910290A2 (en) * 2005-06-30 2008-04-16 Prosidion Limited Gpcr agonists

Also Published As

Publication number Publication date
EP2321297A1 (en) 2011-05-18
CN102083813A (zh) 2011-06-01
WO2010004343A1 (en) 2010-01-14
US20110269734A1 (en) 2011-11-03
ZA201008955B (en) 2011-08-31
IL209978A0 (en) 2011-02-28
MA32467B1 (fr) 2011-07-03
MX2011000060A (es) 2011-02-22
JP2011527331A (ja) 2011-10-27
CA2728042A1 (en) 2010-01-14
AU2009269772A1 (en) 2010-01-14
CL2011000051A1 (es) 2012-03-16
PE20110329A1 (es) 2011-06-03
EA201170151A1 (ru) 2011-08-30

Similar Documents

Publication Publication Date Title
KR20110036609A (ko) 피페리디닐 ｇｐｃｒ 작용제
EP2321308B1 (en) Piperidine gpcr agonists
EP2114935B1 (en) Piperidine gpcr agonists
EP2114931B1 (en) Piperidine gpcr agonists
US8173807B2 (en) Pyridine, pyrimidine and pyrazine derivatives as GPCR agonists
US20110212939A1 (en) Heterocyclic GPCR Agonists
EP2114933B1 (en) Piperidine gpcr agonists
EP2318399B1 (en) Piperidinyl gpcr agonists
JP2011500658A (ja) アゼチジニルｇタンパク質共役受容体アゴニスト
JP2010514830A (ja) ピペリジンｇｐｃｒアゴニスト
HK1158192B (en) Piperidine gpcr agonists
HK1135704B (en) Piperidine gpcr agonists
HK1135705B (en) Piperidine gpcr agonists
HK1163680A (en) Piperidine gpcr agonists
HK1157329B (en) Piperidinyl gpcr agonists
HK1135703B (en) Piperidine gpcr agonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid